Smartphone app
Otherartificial intelligence (AI) smartphone app to provide support for medication adherence
NCT Number: NCT04046497
The aims of this project is to use an artificial intelligence (AI) smartphone app to provide support for medication adherence by patients with first episode psychosis.
Interested in participating?
Request Info15 year–40 year
All sexes
Interventional
Phase 4
Citrus Health, Hialeah, Florida, United States
The challenge of oral medication adherence in first-episode psychosis (as in any potentially chronic illness) is enormous, and numerous studies have linked non-adherence to increased rates of relapse/ hospitalization. Determining whether a patient is adhering to medication is a challenge. Pill counts, pharmacy records, technology-assisted monitoring, biological assays, and a range of self-report and interviewer-rated scales have been employed. In other areas of medicine such as antiretroviral treatment Direct Observation of Treatment (DOT) has been employed with excellent success both in monitoring and demonstrated improvement of important clinical outcomes. DOT is clearly not feasible in community settings. An artificial Intelligence (AI) platform that can be downloaded as an application onto a smart phone app represents a novel approach to offering DOT to support participant oral medication adherence and thereby improve outcomes. Aims of the project are: 1) to document acceptability to patients of the AI smartphone app based upon participation in the study and 2) to compare rates of hospitalization and emergency room visits between participants who receive the AI smartphone app with participants who receive standard care.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
artificial intelligence (AI) smartphone app to provide support for medication adherence
Usual Care provided by CSC clinic
Time frame: 12 months
Provides participant utilization of psychiatric ER visits or psychiatric hospitalization
Contact information is provided by the study sponsor or research team.
Cristina Gonzalez, MS
CONTACT
Patricia Marcy, BSN
CONTACT
Northwell Health
Other
Early-phase Schizophrenia: Practice-based Research to Improve Outcomes (ESPRITO) - Using Artificial Intelligence to Measure Adherence to Oral Medication
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06774417
Clinical High Risk, Early Psychosis
New York, United States
View Trial DetailsNCT07122531
Acid-Base Imbalance, Acidosis
Sherbrooke, Quebec, Canada
View Trial DetailsNCT06774430
Clinical High Risk, Early Psychosis
New York, United States
View Trial DetailsNCT04889911
First Episode Psychosis, Youth
Indianapolis, Indiana, United States
View Trial Details